AP2048A - Diazepinoindole derivatives as kinase inhibitors - Google Patents

Diazepinoindole derivatives as kinase inhibitors

Info

Publication number
AP2048A
AP2048A AP2005003353A AP2005003353A AP2048A AP 2048 A AP2048 A AP 2048A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2048 A AP2048 A AP 2048A
Authority
AP
ARIPO
Prior art keywords
kinase inhibitors
diazepinoindole
derivatives
diazepinoindole derivatives
kinase
Prior art date
Application number
AP2005003353A
Other languages
English (en)
Other versions
AP2005003353A0 (en
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2005003353A0 publication Critical patent/AP2005003353A0/xx
Application granted granted Critical
Publication of AP2048A publication Critical patent/AP2048A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2005003353A 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors AP2048A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2005003353A0 AP2005003353A0 (en) 2005-09-30
AP2048A true AP2048A (en) 2009-09-24

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003353A AP2048A (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Country Status (34)

Country Link
US (3) US6967198B2 (is)
EP (2) EP1947102A1 (is)
JP (1) JP3990718B2 (is)
KR (1) KR100697746B1 (is)
CN (1) CN1759118B (is)
AP (1) AP2048A (is)
AT (1) ATE404564T1 (is)
AU (1) AU2004203977B2 (is)
BR (1) BRPI0406701A (is)
CA (1) CA2512683C (is)
CR (1) CR7899A (is)
CY (1) CY1108408T1 (is)
DE (1) DE602004015724D1 (is)
DK (1) DK1585749T3 (is)
EA (1) EA009337B1 (is)
EC (1) ECSP055911A (is)
ES (1) ES2309484T3 (is)
GE (1) GEP20084367B (is)
HR (1) HRP20050624A2 (is)
IL (1) IL169082A (is)
IS (1) IS7884A (is)
MA (1) MA27703A1 (is)
MX (1) MXPA05007352A (is)
NO (1) NO20053775L (is)
NZ (1) NZ540638A (is)
OA (1) OA13017A (is)
PL (1) PL378372A1 (is)
PT (1) PT1585749E (is)
RS (1) RS20050522A (is)
SI (1) SI1585749T1 (is)
TN (1) TNSN05176A1 (is)
UA (1) UA80733C2 (is)
WO (1) WO2004063198A1 (is)
ZA (1) ZA200504674B (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
DK1585749T3 (da) * 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer
PL1853721T3 (pl) * 2005-02-18 2010-08-31 Astrazeneca Ab Sposób określania wrażliwości na inhibitory CHK1
WO2006105262A1 (en) 2005-03-29 2006-10-05 Icos Corporation HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
JP2009505989A (ja) * 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＶＥＧＦによって活性化されるＦａｓリガンド
EP1942193A4 (en) 2005-08-25 2010-10-27 Ube Industries METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE (S OR R) -AMINOIC ACID OR AN OPTICALLY ACTIVE (S OR R) -α-AMINO-ACID ESTER
EP1916896A4 (en) * 2005-08-26 2010-08-11 Univ California NOT STEROID-antiandrogens
RU2409361C2 (ru) * 2006-04-04 2011-01-20 Пфайзер Продактс Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ
CA2648369A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EP2086644A2 (en) * 2006-11-17 2009-08-12 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
WO2010040527A1 (en) * 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
NZ626937A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
RS56616B1 (sr) * 2011-12-31 2018-02-28 Beigene Ltd Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
CN107922425B (zh) * 2015-08-25 2021-06-01 百济神州有限公司 制备parp抑制剂、结晶形式的方法及其用途
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
BR112020005489A2 (pt) * 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP2022523028A (ja) * 2019-01-25 2022-04-21 ヌメディー， インコーポレイテッド 特発性肺線維症を処置するための方法
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
ES3014705T3 (en) 2019-11-29 2025-04-24 Novaonco Js Therapeutics Co Ltd Diazaindole derivative and use thereof as chk1 inhibitor
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (en) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
EP1144609B1 (en) 1999-08-27 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
JP4610828B2 (ja) 1999-09-22 2011-01-12 株式会社 キャンバス Ｇ２期細胞周期停止の阻害、およびｄｎａ損傷剤に対する細胞感作のための組成物および方法
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
DK1585749T3 (da) * 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (en) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Also Published As

Publication number Publication date
CY1108408T1 (el) 2014-02-12
MA27703A1 (fr) 2006-01-02
RS20050522A (sr) 2007-12-31
ES2309484T3 (es) 2008-12-16
US20060004052A1 (en) 2006-01-05
KR20050092397A (ko) 2005-09-21
BRPI0406701A (pt) 2005-12-20
EA009337B1 (ru) 2007-12-28
SI1585749T1 (sl) 2008-10-31
CR7899A (es) 2005-08-05
OA13017A (en) 2006-11-10
WO2004063198A1 (en) 2004-07-29
US7462713B2 (en) 2008-12-09
NO20053775D0 (no) 2005-08-08
GEP20084367B (en) 2008-05-13
CN1759118A (zh) 2006-04-12
CN1759118B (zh) 2010-12-08
US20050075499A1 (en) 2005-04-07
NO20053775L (no) 2005-09-16
US7132533B2 (en) 2006-11-07
NZ540638A (en) 2007-12-21
ATE404564T1 (de) 2008-08-15
EA200500893A1 (ru) 2006-02-24
IS7884A (is) 2005-06-09
US6967198B2 (en) 2005-11-22
JP3990718B2 (ja) 2007-10-17
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
JP2006516274A (ja) 2006-06-29
AU2004203977B2 (en) 2010-06-17
HK1086257A1 (en) 2006-09-15
TNSN05176A1 (fr) 2007-06-11
MXPA05007352A (es) 2006-02-17
IL169082A (en) 2011-02-28
ZA200504674B (en) 2006-07-26
HRP20050624A2 (en) 2006-02-28
ECSP055911A (es) 2005-11-22
CA2512683A1 (en) 2004-07-29
US20070135415A1 (en) 2007-06-14
EP1947102A1 (en) 2008-07-23
UA80733C2 (en) 2007-10-25
DK1585749T3 (da) 2008-09-22
EP1585749A1 (en) 2005-10-19
DE602004015724D1 (de) 2008-09-25
KR100697746B1 (ko) 2007-03-22
PT1585749E (pt) 2008-10-23
CA2512683C (en) 2010-03-16
AP2005003353A0 (en) 2005-09-30
PL378372A1 (pl) 2006-04-03

Similar Documents

Publication Publication Date Title
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP1496910A4 (en) KINASE INHIBITORS
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1558609A4 (en) KINASE INHIBITORS
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
GB2423083B (en) Azole-based kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1812424A4 (en) Kinase Inhibitors
EP1569907A4 (en) NICOTINAMIDE-BASED KINASE HEMMER
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
HK1086560A (en) Thienopyridone derivatives as kinase inhibitors
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze